Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists

Authors: Amr Ahmed* and Maher Monir. Akl

DOI: 10.23880/cclsj-16000199

Volume 9, Issue 1

Abstract

Prediabetes, a condition characterized by elevated blood sugar levels, poses a significant health risk as it increases the likelihood of developing type 2 diabetes, heart disease, and stroke. Despite its prevalence, early detection and intervention can prevent its progression [1]. Global Prevalence of Impaired Glucose Tolerance (IGT); In 2017, the global prevalence of IGT was estimated at 7.3%, affecting 352.1 million individuals [2]. Projections for 2045 indicate an alarming increase to 8.3%, equivalent to 587 million individuals. Prediabetes affects various age groups, with no significant gender difference, and nearly half of those with IGT are under 50 years old. According to the CDC, approximately 38.0% of the adult US population, totaling 97.6 million individuals, has prediabetes. Among those aged 65 years or older, 48.8% (27.2 million) are affected [2].

Keywords: GLP1 RA Agonists; Reprogramming; Beta Cells; Prediabtes; Albumin; Type II Diabetes

View PDF